New drug cocktail aims to fight metastatic colorectal cancer
NCT ID NCT06882915
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a combination of three drugs—TAS-102, bevacizumab, and serplulimab—in 20 people with metastatic colorectal cancer who have already had surgery to remove tumors. The goal is to see if the combination is safe and can delay cancer progression. Participants must have failed standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trifluridine/tipiracil (TAS-102) combined with bevacizumab and serplulimab
- What this could lead to
- If this works, it could offer a new treatment option for people with metastatic colorectal cancer who have not responded to standard therapies, potentially extending survival.
- What could go wrong
- This is a very early Phase 1 trial with only 20 people, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Why are more younger adults getting colorectal cancer? a national study digs into the data
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?